Skip to main content
. 2019 Sep 24;12:7857–7864. doi: 10.2147/OTT.S171665

Figure 1.

Figure 1

Reported objective response rates of multi-kinase inhibitors and selective RET-inhibitors. Cabozantinib,44 Vandetanib,43 Lenvatinib,46 LOXO-292,53 BLU-667,54,55 RXDX-105.58